For the first time since 2019, our team attended one of the signature global events for the interventional cardiovascular community: EuroPCR. The course is an opportunity to engage with the physician community to demonstrate our technology, and we welcomed the return to an in-person event. Two years have passed since the last event, which provided a fresh perspective on how clinicians view robotic technologies.

Wayne Markowitz, Worldwide Executive Vice President and Head of Corindus and Carrie Vooght, Head of Clinical Affairs, both attended EuroPCR and shared their key takeaways: 

The evolutionary path of our CorPath^® GRX is approaching several major milestones in 2022 that mark the next steps in our mission to revolutionize interventional treatment and expand access to care. The demand for innovative and transformative technology has never been greater and we are poised to meet the market’s demand for innovation.

As we close 2021 and look ahead to the new year, these are some of the projects that will reshape our technology in 2022:

The iteration of robotic platforms that healthcare providers use today, such as CorPath® GRX, are fairly new technologies, but the ideas and motivations that spurred their development have been intrinsic to medicine for more than a century. Providers have long searched for ways to improve the quality of care by increasing efficiency, and even simplistic technologies have contributed to that cause.

Healthcare providers around the world have set out on a mission to achieve one thing: predictability. In the aftermath of a pandemic that has been anything but predictable, every stakeholder in the healthcare continuum has a vested interest in making it easier to predict positive patient outcomes.

Several of our female CorPath^® GRX users from across the globe have contributed to the American College of Cardiology’s Women in Cardiology section. Featured prominently in the “#ChooseCardiology” column, each of the physicians discusses their path to interventional cardiology and the role that robotic-assisted intervention plays. Read on to learn more about these dynamic women.

About an hour outside of Brussels sits a state-of-the-art innovation center that is an ideal venue for Corindus to demonstrate its CorPath^® GRX robot to interventionalists and catheterization laboratory staff. In 2010, Dr. Alexandre Mottrie, a pioneer in robotic surgery, founded the O.L.V. Vattikuti Robotic Surgery Institute (ORSI), a multidisciplinary school of robotic surgery. In its first few years, ORSI implemented two surgical robotic systems to train urologists and gynecologists from Europe. In 2016, ORSI rebranded to become Orsi Academy, and broadened its scope so that stakeholders across several specialties could collaborate to improve the best practices in minimally invasive surgery through training, R&D, and data management. By 2017, Orsi Academy had become – and still is – the largest robotics training center in the world, and recently completed construction of a new state-of-the-art campus.

In October 2019, Dr. Ryan Madder sat in front of a control panel in Waltham, MA, preparing for a robotic-assisted percutaneous coronary intervention (PCI) as he has done on countless occasions. Beyond the familiarity of the robotic controls and monitor with fluoroscopic images of the heart, this was anything but a typical procedure. While Dr. Madder sat outside Boston, he was about to attempt PCI on simulated patients located in New York and San Francisco.